Skip to content

8-KAccepted May 18, 8:56 AM ET

Evofem Biosciences Reports Q1 2026 Financial Results

EVFMEvofem Biosciences, Inc.

Accepted (ET)

8:56 AM

May 18, 2026

Filed

May 18, 2026

Documents

13

Size

292.3 KB

Summary

Evofem Biosciences Reports Q1 2026 Financial Results

Updated

What Happened

  • On May 18, 2026, Evofem Biosciences, Inc. announced and furnished a press release reporting its financial results for the three months ended March 31, 2026. The announcement was made via a Current Report on Form 8-K under Item 2.02.

Key Details

  • Filing date: May 18, 2026 (Form 8-K, Item 2.02).
  • Reporting period: three months ended March 31, 2026 (quarterly results / earnings).
  • Press release furnished as Exhibit 99.1 to the Form 8-K.
  • Cover Page Interactive Data (Inline XBRL) furnished as Exhibit 104.

Why It Matters

  • This 8-K provides the company’s latest quarterly results and is the official source for investors to see updated earnings, revenue, and financial condition for the stated quarter.
  • Investors should review the furnished press release (Exhibit 99.1) and the company’s subsequent filings for the specific numbers (revenue, net income/loss, cash position, guidance) that could affect valuation and near-term trading decisions.

AI-written summary · check the filing